Current version snapshot

Not FDA-approved↗Safety records↗

Current · version 3: GHK-Cu↗↗

Related names recorded in this version: Copper tripeptide-1, GHK copper↗

A copper-binding peptide that FDA lists, except in injected forms, as under evaluation for pharmacy compounding. None of the sources reviewed reports an FDA approval.↗

This immutable URL preserves the current public version.
The canonical profile remains the primary reading view. Read the canonical profile.
Update · November 14, 2026

We added a plain-language reader guide with cited answers, re-checked FDA’s May 2026 503A nominations list, added FDA’s compounding safety-risk page and two randomized studies from our human evidence review, and noted that HHS’s October 30, 2026 draft enforcement-discretion policy does not include GHK-Cu. 137

What this version reported

Two randomized studies of copper-peptide skin and wound products report mixed results. FDA lists injected GHK-Cu among substances that may present significant safety risks. GHK-Cu is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.↗↗↗↗

Organizations named in cited records:
  • U.S. Food and Drug Administration↗
  • U.S. Department of Health and Human Services↗

Reader guide in this version

Key takeaway

GHK-Cu, also called copper tripeptide-1, is a small peptide bound to copper that is used in skin-care research.2,5 None of the sources reviewed here reports an FDA approval of GHK-Cu. Since May 2026, FDA has listed GHK-Cu, except in injected forms, as under evaluation for the list of substances pharmacies may use in compounding.1 FDA lists injected GHK-Cu among compounding substances that may present significant safety risks, noting possible immune reactions and limited human data.3 GHK-Cu is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.7

At a glance

What it is
A copper-binding tripeptide, a chain of three amino acids (glycyl-histidyl-lysine) bound to copper, recorded by FDA as copper tripeptide-1.2,4
FDA status
No FDA approval is reported in the sources reviewed here. FDA lists GHK-Cu, except in injected forms, in category 1 (under evaluation) for the 503A compounding list, and lists injected GHK-Cu among withdrawn nominations with safety concerns.1,3
Human evidence
Two randomized studies of copper-peptide skin and wound products, one of them very small, with mixed results.4,5
Evidence strength
Smaller controlled human trials

What is GHK-Cu?

GHK-Cu is a complex of copper with a three-amino-acid peptide, glycyl-L-histidyl-L-lysine. FDA’s substance registry records it as copper tripeptide-1.2,4

Published human studies have tested it in wound-care and skin-care products.4,5

How is GHK-Cu thought to work?

GHK-Cu has been studied for wound healing and skin repair, but the sources reviewed here do not establish how it works in people.4,5

FDA’s safety-risk page notes that injected GHK-Cu could provoke immune reactions because of possible clumping of the peptide and peptide-related impurities.3

What do human studies show?

In a multicenter randomized study in people with diabetic foot ulcers, the authors reported greater ulcer closure and fewer infections with a copper-peptide gel than with an inactive gel in one comparison. The abstract does not give the total number of participants.4

In a small randomized study after laser skin resurfacing, 13 people completed 12 weeks of skin care with or without GHK-Cu. Blinded and computer assessments found no significant differences in redness, wrinkles or overall skin quality, although participants rated their skin better with GHK-Cu.5

FDA states that there are limited human data to inform the safety of injected GHK-Cu.3

What the evidence base contains

  • Controlled human trial A multicenter, randomized, evaluator-blinded study comparing a copper-peptide gel with an inactive gel, alongside standard wound care, in people with diabetic foot ulcers. The published abstract does not give the total number of participants.4
  • Controlled human trial A small randomized study in which 13 people completed skin-care routines with or without GHK-Cu after laser skin resurfacing and were followed for 12 weeks.5

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is GHK-Cu FDA-approved?

None of the sources reviewed here reports an approval of GHK-Cu by FDA. FDA’s records reviewed here concern its status for pharmacy compounding.1,3

FDA’s list of substances nominated under section 503A, updated May 14, 2026, places GHK-Cu, except in injected forms, back in category 1, meaning under evaluation. FDA explains that it had removed GHK-Cu on April 22, 2026 after nominations were withdrawn, but that one nominator clarified on May 5, 2026 that it meant to withdraw only the injected form.1

The same list states that FDA intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027 about whether GHK-Cu should be added to the 503A bulks list.1

FDA’s compounding safety-risk page, current as of April 22, 2026, lists injected GHK-Cu among substances whose nominations were withdrawn, citing possible immune reactions and limited human safety data.3

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. GHK-Cu is not among them.6,7

Timeline

  1. Results of a randomized study of a copper-peptide gel in diabetic foot ulcers are published.4
  2. Results of a small randomized study of GHK-Cu skin care after laser resurfacing are published.5
  3. FDA removes GHK-Cu from category 1 after nominations are withdrawn, and its safety-risk page lists injected GHK-Cu among withdrawn nominations.1,3
  4. FDA restores GHK-Cu, except in injected forms, to category 1 of its 503A nominations list.1

What is still unknown?

Whether GHK-Cu has a clinical benefit: the two randomized studies reviewed here had mixed results, and one was very small.4,5

The safety of injected GHK-Cu, for which FDA says human data are limited.3

What FDA will decide after consulting its advisory committee, which it said it intends to do before the end of February 2027.1

Sources for this version

  1. 1
    503A bulk drug substances under evaluation · GHK-Cu except injectable routes · updated May 14, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked July 22, 2026

  2. 2
    Copper tripeptide-1 substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked July 29, 2026

  3. 3
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  4. 4
    Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper (1994) · PMID 17147644 ↗

    Wound Repair and Regeneration · Official source · Source checked November 14, 2026

  5. 5
    Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin (2006) · PMID 16847171 ↗

    Archives of Facial Plastic Surgery · Official source · Source checked November 14, 2026

  6. 6
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  7. 7
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026